PE20081351A1 - QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTS - Google Patents

QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTS

Info

Publication number
PE20081351A1
PE20081351A1 PE2007001740A PE2007001740A PE20081351A1 PE 20081351 A1 PE20081351 A1 PE 20081351A1 PE 2007001740 A PE2007001740 A PE 2007001740A PE 2007001740 A PE2007001740 A PE 2007001740A PE 20081351 A1 PE20081351 A1 PE 20081351A1
Authority
PE
Peru
Prior art keywords
cancer agents
ethyl
amino
quinazoline derivatives
quinazolin
Prior art date
Application number
PE2007001740A
Other languages
Spanish (es)
Inventor
Brian Aquila
Donald James Cook
Stephen Lee
Paul Lyne
Melissa Vasbinder
Haixia Wang
Craig Johnstone
David Alan Rudge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39386079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081351(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081351A1 publication Critical patent/PE20081351A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

REFERIDA A UN DERIVADO DE QUINAZOLINA DE FORMULA (I), DONDE R1 ES HALOGENO, NITRO, CIANO, OH, TRIFLUOROMETOXI, ENTRE OTROS; n ES UN ENTERO DE 0 A 4; R2 ES HALOGENO, AMINO, CARBAMOILO, CARBOXI, ENTRE OTROS; m ES UN ENTERO DE 0 A 4. SON COMPUESTOS PREFERIDOS: N-[(1R)-1-(4-{[6-(4-METILPIRIDIN-3-IL)QUINAZOLIN-2-IL]AMINO}FENIL)ETIL]ACETAMIDA, 4-(6-BROMOQUINAZOLIN-2-ILAMINO)-N-(2-(DIMETILAMINO)ETIL)BENCENSULFONAMIDA, 3-METOXI-N-[(1R)-1-(4-{[6-(4-METILPIRIDIN-3-IL)QUINAZOLIN-2-IL]AMINO}FENIL)ETIL]PROPANAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINASA B-RAF Y SON UTILES COMO AGENTES ANTICANCERIGENOSREFERRED TO A QUINAZOLINE DERIVATIVE OF FORMULA (I), WHERE R1 IS HALOGEN, NITRO, CYANE, OH, TRIFLUOROMETOXI, AMONG OTHERS; n IS AN INTEGER FROM 0 TO 4; R2 IS HALOGEN, AMINO, CARBAMOYL, CARBOXI, AMONG OTHERS; m IS AN INTEGER FROM 0 TO 4. PREFERRED COMPOUNDS ARE: N - [(1R) -1- (4 - {[6- (4-METHYLPYRIDIN-3-IL) QUINAZOLIN-2-IL] AMINO} PHENYL) ETHYL] ACETAMIDE, 4- (6-BROMOQUINAZOLIN-2-ILAMINO) -N- (2- (DIMETHYLAMINE) ETHYL) BENCENSULFONAMIDE, 3-METHOXY-N - [(1R) -1- (4 - {[6- (4-METHYLPYRIDIN -3-IL) QUINAZOLIN-2-IL] AMINO} PHENYL) ETHYL] PROPANAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCESS AND A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF PROTEIN KINASE B-RAF AND ARE USEFUL AS ANTI-CANCER AGENTS.

PE2007001740A 2006-12-08 2007-12-07 QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTS PE20081351A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86924106P 2006-12-08 2006-12-08
US98573207P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
PE20081351A1 true PE20081351A1 (en) 2008-11-26

Family

ID=39386079

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001740A PE20081351A1 (en) 2006-12-08 2007-12-07 QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTS

Country Status (5)

Country Link
AR (1) AR064208A1 (en)
CL (1) CL2007003557A1 (en)
PE (1) PE20081351A1 (en)
TW (1) TW200829566A (en)
WO (1) WO2008068507A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Fast Dissociting Dopamine 2 Receptor Antagonists
CN101652352A (en) * 2006-12-22 2010-02-17 诺瓦提斯公司 Quinazolines for PDK1 inhibition
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Fast -Dissociating Dopamine 2 Receptor Antagonists
ES2400710T3 (en) 2007-04-23 2013-04-11 Janssen Pharmaceutica, N.V. Tia (dia) zoles as fast dissociation dopamine 2 receptor antagonists
US8906921B2 (en) 2007-04-23 2014-12-09 Janssen Pharmaceutica Nv 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
EA019048B1 (en) 2008-07-31 2013-12-30 Янссен Фармацевтика Нв Piperazin-1-yl-trifluoromethyl-substituted pyridines as fast dissociating dopamine 2 receptor antagonists
PE20120110A1 (en) 2009-02-13 2012-02-20 Fovea Pharmaceuticals [1,2,4] TRIAZOLO [1,5-A] PYRIDINES AS KINASE INHIBITORS
AR081960A1 (en) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa HETEROCICLICAL COMPOUNDS, ITS PREPARATION AND THERAPEUTIC APPLICATION
US10554578B2 (en) 2015-06-30 2020-02-04 British Telecommunications Public Limited Company Quality of service management in a network
EP3507382B1 (en) 2016-09-02 2021-06-23 New England Biolabs, Inc. Analysis of chromatin using a nicking enzyme
CN111170986A (en) * 2018-11-13 2020-05-19 北京睿熙生物科技有限公司 Inhibitors of bruton's tyrosine kinase
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023138412A1 (en) * 2022-01-20 2023-07-27 Insilico Medicine Ip Limited Fused pyrimidin-2-amine compounds as cdk20 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2542329A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
AR064208A1 (en) 2009-03-18
CL2007003557A1 (en) 2008-08-01
TW200829566A (en) 2008-07-16
WO2008068507A2 (en) 2008-06-12
WO2008068507A3 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
PE20081351A1 (en) QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTS
PE20081393A1 (en) QUINOLINE DERIVATIVES AS INHIBITORS OF CSF-1R
PE20120814A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
PE20090434A1 (en) SULFONIL AMIDE DERIVATIVES AS KINASE INHIBITORS
PE20141700A1 (en) 2- (2,4,5-ANILINE SUBSTITUTED) PYRIMIDINE COMPOUNDS
EA200970585A1 (en) BENZAMIDE DERIVATIVES AS AGONISTS OF EP RECEPTORS
GT200600105A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS.
PE20090837A1 (en) NEW CHEMICALS
PE20090210A1 (en) COMPOUNDS DERIVED FROM PYRAZOLO PYRIMIDINE AS INHIBITORS OF JAK QUINASE
IL177280A (en) Crystalline monohydrate of a 2-aminothiazole-5-aromatic carboxamide, process for preparing same, pharmaceutical composition comprising same and use thereof for preparation of a medicament
PE20061373A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 'N- (2-CHLORO-6-METHYLPHENIL) -2 - [[6- [4- (2-HYDROXYETHYL) -1-PIPERAZINYL] -2-METHYL-4-PYRIMIDINYL] AMINO] -5- THIAZOLCARBOXAMIDE
PE20070113A1 (en) QUINOLINE AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AND TRKB TYROSINQUINASES
NZ593295A (en) Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor
UY28885A1 (en) 4-PHENYLAMINE-QUINAZOLIN-6-IL-AMIDAS CROSSED REFERENCE ON RELATED APPLICATION (S)
BRPI0514750A (en) 7-amino-3-phenyl-dihydropyrime [4,5-d] pyrimidinones amide derivatives, their manufacture and use as protein kinase inhibitors
PE20040647A1 (en) TYROSINE KINE INHIBITORS
PE20091623A1 (en) 1H-PYRAZOLO [3,4-b] PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS
EA200701705A1 (en) ANTAGONISTS GLUCAGON RECEPTORS, OBTAINING AND THERAPEUTIC APPLICATION
PE20081256A1 (en) TRIAZALOPYRIDACINE AS A MODULATOR OF PROTEIN KINASE ACTIVITY
PE20061394A1 (en) METABOLITES OF N- (2-CHLORO-6-METHYLPHENYL) -2 - [[6- [4- (2-HYDROXYETHYL) -1-PIPERAZINYL] -2-METHYL-4-PYRIMIDINYL] AMINO] -5-THIAZOLCARBOXAMIDES
NO20063620L (en) Arylaniline derivatives as beta2 adrenergic receptor agonists
EA201001769A1 (en) DERIVATIVES OF QUINOLINES AND QUINOXALINS AS PROTEINTHYROSINKINASE INHIBITORS
EA200870461A1 (en) Lactam Derivatives of Cyclohexylimidazole as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1
PE20100138A1 (en) MORPHOLIN PYRIMIDINE DERIVATIVES USED IN MTOR KINASE AND / OR PI3K-RELATED DISEASES
PE20121314A1 (en) DERIVATIVES OF SUBSTITUTED 4-AMINOCICLOHEXANE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal